title: Long-term follow-up of patients with subacute sclerosing panencephalitis treated with inosiplex.
abstract: During the past five years, 15 patients with subacute sclerosing panencephalitis (SSPE) were treated with inosiplex. Using a disability index specifically designed for the disease, this study monitored the course of SSPE in each patient before and during inosiplex therapy. Posttreatment follow-up ranged from 2 to 144 months. Inosiplex had an apparently beneficial effect on morbidity and mortality in 10 of the 15 patients tested. Eight improved immediately after treatment, 2 had a delayed improvement, and 1 patient stabilized. Four patients followed a typical course for SSPE and died a mean 9 months after onset. Treatment was not associated with adverse reactions. Due to its low risk-benefit ratio, inosiplex is recommended for continuous use in SSPE even after extended remissions.
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007288:Inosine / Q000031:analogs & derivatives*; D007542:Inosine Pranobex / Q000627:therapeutic use*; D008297:Male; D008457:Measles / Q000150:complications; D009460:Neurologic Examination; D013344:Subacute Sclerosing Panencephalitis / Q000188:drug therapy*
chemical_list: D007288:Inosine; D007542:Inosine Pranobex